Arbutus to Present at Jefferies Healthcare Conference
May 31 2023 - 7:30AM
Arbutus Biopharma Corporation (Nasdaq: ABUS) (“Arbutus” or the
“Company”), a clinical-stage biopharmaceutical company leveraging
its extensive virology expertise to develop novel therapeutics that
target specific viral diseases, today announced that the Company
will participate in a fireside chat at the Jefferies Healthcare
Conference taking place in New York on Wednesday, June 7, 2023 at
9:30 am ET.
Presenters: William Collier, President &
Chief Executive Officer; Dr. Michael Sofia, Chief Scientific Offer;
and David Hastings, Chief Financial Officer.
A live webcast of the fireside chat can be
accessed through the Investors section of Arbutus' website at
www.arbutusbio.com. An archived replay of the webcast will be
available on the Arbutus website after the event.
About Arbutus
Arbutus Biopharma Corporation (Nasdaq: ABUS) is
a clinical-stage biopharmaceutical company leveraging its extensive
virology expertise to develop novel therapeutics that target
specific viral diseases. Our current focus areas include Hepatitis
B virus (HBV), SARS-CoV-2, and other coronaviruses. To address HBV,
we are developing a RNAi therapeutic, an oral PD-L1 inhibitor, and
an oral RNA destabilizer to potentially identify a combination
regimen with the aim of providing a functional cure for patients
with chronic HBV by suppressing viral replication, reducing surface
antigen and reawakening the immune system. We believe our lead
compound, AB-729, is the only RNAi therapeutic with evidence of
immune re-awakening. AB-729 is currently being evaluated in
multiple phase 2 clinical trials. We also have an ongoing drug
discovery and development program directed to identifying novel,
orally active agents for treating coronaviruses, (including
SARS-CoV-2), for which we have nominated a compound and have begun
IND-enabling pre-clinical studies. In addition, we are also
exploring oncology applications for our internal PD-L1 portfolio.
For more information, visit www.arbutusbio.com.
Contact Information
Investors and Media
Lisa M. CaperelliVice President, Investor RelationsPhone:
215-206-1822Email: lcaperelli@arbutusbio.com
Arbutus Biopharma (NASDAQ:ABUS)
Historical Stock Chart
From Mar 2024 to Apr 2024
Arbutus Biopharma (NASDAQ:ABUS)
Historical Stock Chart
From Apr 2023 to Apr 2024